Evidence- and Value-Based Approaches to Pathology and Laboratory Diagnosis and Prognosis of Common Hematologic Neoplasms: A Case-Based Illustration

Atlanta Marriott Marquis Symposium Room: Atrium A Atlanta, Georgia December 8, 2017

 

Description

This program’s overall objective is to update the practicing hematologists/oncologists and hematopathologists about the evolving repertoire of test options and appropriate testing strategies. We aim to inform participants on the most cost-effective, diagnostically efficient testing strategies in the evaluation of hematologic malignancies. Using data-driven testing algorithms derived from the Mayo Clinic Hematopathology/Hematology practice and available literature, we will illustrate how unnecessary, redundant, and costly laboratory tests can be eliminated from the participants’ practices while maintaining the highest quality medical care.  

Intended Audience

Hematologists/Oncologists, hematopathologists, pathologists, physician assistants, and nurse practitioners who provide care for patients with hematological neoplasms.  

Objectives

Upon completion of the conference, participants should be able to:

• Describe the algorithmic strategy for the diagnostic workup of diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
• Discuss the utility of next-generation sequencing in myeloid malignancies.
• Discuss an evidence-based, algorithmic approach to the bone marrow workup of eosinophilia.
• Use algorithm-based stratification of patients for optimal treatment choice.

 

Agenda

View Full Agenda  

Symposium Faculty

Faculty Disclosure

Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.

National Physician Payment Transparency Program

Mayo Medical Laboratories is not an applicable manufacturer or applicable group purchasing organization (GPO). (GPOs, per the Centers for Medicare & Medicaid Services, and this program do not trigger any reporting requirements pursuant to Open Payments[Sunshine Act] legislation.)  

Presentations

Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Update Per the 2016 Revision of the WHO Classification of Lymphoid

 

Algorithmic Approach in the Diagnosis and Treatment of Multiple Myeloma

 

Eosinophilia Optimizing Test Utilization in the Bone Marrow Workup

 

Next-Generation Sequencing Testing in Myeloid Malignancies: AML and Chronic Myelomonocytic Leukemia Case Examples